News

As we approach the end of 2023, we are pleased to share a selection of recently completed appointments and initiated searches with our valued clients.

PIR International is pleased to announce the appointment of Beverley Carr as Chief Business Officer at CHARM Therapeutics. CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines. CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines. Beverley brings extensive business development experience, with a career spanning over a decade at GSK and several leading biotechnology companies. She joins CHARM from Amphista Therapeutics, where she served as Interim Chief [...]

PIR International is pleased to announce the appointment of Luba Greenwood as Non-Executive Chair at Closed Loop Medicine. Closed Loop Medicine is a TechBio company enhancing drug development through AI, machine learning, and personalized dosing, to bring forward the promise of precision care. The Company’s proprietary platform enhances treatment options by seamlessly integrating drugs and devices with patient-led digital experiences and closed-loop models of care – all under a single prescription. Working in combination with an expanding portfolio of new and established medicines, Closed Loop Medicine’s scalable approach to treating the individual, not just the disease, has the potential to [...]

PIR International is pleased to announce the appointment of Dieter Weinand as Non-Executive Chair at Anaveon. Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The Company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. The organisation’s mission is to harness the power of the immune system for life-saving treatments. Dieter is an experienced business leader in the pharmaceutical industry and is the former Chair and CEO of Bayer Pharmaceuticals. During a career stretching back [...]

As we approach the end of 2023, we are pleased to share a selection of recently completed appointments and initiated searches with our valued clients.

PIR International is pleased to announce the placement of Giles Brown as SVP of Chemistry at Amphista Therapeutics. Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, is applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the lives of patients with severe diseases including cancer and central nervous system diseases. Giles joins Amphista with over 20 years’ experience in medicinal chemistry during which he contributed to the discovery and development of fifteen preclinical candidates, of which seven successfully entered [...]

PIR International is pleased to announce the placement of Daniel Brennan as SVP, Corporate and Commercial Strategy at NMD Pharma. NMD Pharma A/S is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. Daniel joins NMD Pharma with over 25 years of strategic commercial experience in the biopharmaceutical industry, having held various senior management roles across the sector. During his career to date, he has led the development of commercial strategies and plans for over 20 biopharmaceutical products across neuroscience, rare disease and hospital products, including 5 successful US product launches in rare [...]

It has been a busy winter period at PIR International, with a number of appointments completed alongside new searches kicking off. We are pleased to share a selection of this recent activity with our valued clients across the UK, Europe and the US.

If you’re weighing up whether to keep this resource in-house or outsource it, I feel that you are missing a key point. In a previous article I wrote about improving hiring processes. As part of that debate, and set against the pressure to cut costs many managers are facing, some companies will be questioning what value they receive from their use of executive search firms, maybe exploring the potential for significant cost savings by taking all search assignments in-house. This is not a new idea. Ever since I’ve worked in human resources I’ve heard a variety of positive and [...]

It has been a highly productive summer period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.